EMAA (9345) Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A (Aktiv)
Zweitlinie oder später
Bayer 18117 An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 (Aktiv)
CLDK378A2407 study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)
GC-LTFU-001 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)
HD-CAR-1/V03 Treatment of patients with CD19+ hematologic disease with T lymphocytes transduced retrovirally with a third generation CAR (Aktiv)
LOXO-IDH-20001 (I9Y-OX-JDHB) Eine Phase-I-Studie mit oralem LY3410738 bei Patienten mit fortgeschrittenen hämatologischen Malignomen mit IDH1- oder IDH2-Mutationen (Aktiv)